SDF-1α upregulation by atorvastatin in rats with acute myocardial infarction via nitric oxide production confers anti-inflammatory and anti-apoptotic effects

Journal of Biomedical Science

Volumn 19, Issue 1, 2012, Pages

  Qiu, Ruofeng ^a   Cai, Anping ^b   Dong, Yugang ^a   Zhou, Yingling ^b   Yu, Danqing ^b   Huang, Yuli ^a   Zheng, Dongdan ^a   Rao, Shaoqi ^a   Feng, Yingqing ^b   Mai, Weiyi ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Acute myocardial infarction; Atorvastatin; Stromal cell derived factor 1alpha

Indexed keywords

ATORVASTATIN; CHEMOKINE RECEPTOR CXCR4; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PLERIXAFOR; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; ANTIINFLAMMATORY AGENT; CXCR4 PROTEIN, RAT; HEPTANOIC ACID DERIVATIVE; HETEROCYCLIC COMPOUND; PYRROLE DERIVATIVE; STAT3 PROTEIN, RAT; STROMAL CELL DERIVED FACTOR 1;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTI APOPTOTIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; DRUG MECHANISM; HEART FUNCTION; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CORONARY BLOOD VESSEL; GENETICS; HEART INFARCTION; LIGATION; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; UPREGULATION;

RATTUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CHEMOKINE CXCL12; CORONARY VESSELS; HEPTANOIC ACIDS; HETEROCYCLIC COMPOUNDS; LIGATION; MALE; MYOCARDIAL INFARCTION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CXCR4; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION;

MLCS; MLOWN;

EID: 84869232677     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-19-99     Document Type: Article

References (23)

1. Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. Elmadbouh I, HKh H, Jiang S, Idris NM, Lu G, Ashraf M, J Mol Cell Cardiol 2007 42 4 792 803 10.1016/j.yjmcc.2007.02.001 17350033 (Pubitemid 46527603)
2. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitmentto the heart after myocardial infarction but is not sufficient to induce homingin the absence of injury. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ, Circulation 2004 110 21 3300 3305 10.1161/01.CIR. 0000147780.30124.CF 15533866 (Pubitemid 39557491)
3. The stromal cell-derived factor-1/CXCR4 axis in cardiac injury and repair. Frangogiannis NG, J Am Coll Cardiol 2011 58 23 2424 2426 10.1016/j.jacc.2011.08.031 22115650
4. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Hu X, Dai S, Wu WJ, et al. Circulation 2007 116 6 654 663 10.1161/CIRCULATIONAHA.106.672451 17646584 (Pubitemid 47356350)
5. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M, Cardiovasc Res 2008 77 1 134 142 18006467 (Pubitemid 351195153)
6. Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acute myocardial infarction. Dong F, Harvey J, Finan A, Weber K, Agarwal U, Penn M, Circulation 2012 Published online before print June 9, 2012
7. SDF-1 in myocardial repair. Penn MS, Pastore J, Miller T, Aras R, Gene Ther 2012 19 6 583 587 10.1038/gt.2012.32 22673496
8. Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1)1: SDF-1 alpha mRNA is selectively induced in rat model of myocardial infarction. Pillarisetti K, Gupta SK, Inflammation 2001 25 5 293 300 10.1023/A:1012808525370 11820456 (Pubitemid 34093585)
9. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Fujii H, Li SH, Wu J, et al. Eur Heart J 2011 32 16 2075 2084 10.1093/eurheartj/ehq475 21196445
10. Mesenchymal stem cells modified with stromal cell-derived factor 1 alpha improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a rat model of myocardial infarction. Tang J, Wang J, Guo L, et al. Mol Cells 2010 29 1 9 19 10.1007/s10059-010-0001-7 20016947
11. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. Zhang M, Mal N, Kiedrowski M, et al. FASEB J 2007 21 12 3197 3207 10.1096/fj.06-6558com 17496162
12. Chemokine, vascular and therapeutic effects of combination Simvastatin and BMSC treatment of stroke. Cui X, Chopp M, Zacharek A, et al. Neurobiol Dis 2009 36 1 35 41 10.1016/j.nbd.2009.06.012 19591934
13. Endothelial nitric oxide synthase promotes bone marrow stromal cell migration to the ischemic myocardium via upregulation of stromal cell-derived factor-1alpha. Li N, Lu X, Zhao X, et al. Stem Cells 2009 27 4 961 970 10.1002/stem.6 19353524
14. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Laufs U, La Fata V, Plutzky J, Liao JK, Circulation 1998 97 12 1129 1135 10.1161/01.CIR.97.12.1129 9537338 (Pubitemid 28152885)
15. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. Bell RM, Yellon DM, J Am Coll Cardiol 2003 41 3 508 515 10.1016/S0735-1097(02)02816-4 12575984 (Pubitemid 36164511)
16. Therapeutic potential of angiogenin modified mesenchymal stem cells: angiogenin improves mesenchymal stem cells survival under hypoxia and enhances vasculogenesis in myocardial infarction. Liu XH, Bai CG, Xu ZY, et al. Microvasc Res 2008 76 1 23 30 10.1016/j.mvr.2008.02.005 18462761
17. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Kureishi Y, Luo Z, Shiojima I, et al. Nat Med 2000 6 9 1004 1010 10.1038/79510 10973320
18. Five-year prognosis in an incident cohort of people presenting with acute myocardial infarction. Simpson CR, Buckley BS, McLernon DJ, Sheikh A, Murphy A, Hannaford PC, PLoS One 2011 6 10 26573 10.1371/journal.pone.0026573 22028911
19. Rapid, direct effects of statin treatment on arterial redox state and nitricoxide bioavailability in human atherosclerosis via tetrahydrobiopterin- mediated endothelial nitric oxide synthase coupling. Antoniades C, Bakogiannis C, Leeson P, et al. Circulation 2011 124 3 335 345 10.1161/CIRCULATIONAHA.110. 985150 21730307
20. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity. Castro PF, Miranda R, Verdejo HE, et al. J Heart Lung Transplant 2008 27 4 435 441 10.1016/j.healun.2008.01.012 18374881 (Pubitemid 351418248)
21. Reduction of infarct size by short-term pretreatment with atorvastatin. Birnbaum Y, Ashitkov T, Uretsky BF, Ballinger S, Motamedi M, Cardiovasc Drugs Ther 2003 17 1 25 30 10.1023/A:1024251607923 12843684 (Pubitemid 36898095)
22. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Rosanio S, Ye Y, Atar S, et al. Cardiovasc Drugs Ther 2006 20 1 27 36 10.1007/s10557-005-5203-4 16435070
23. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Razavi HM, Hamilton JA, Feng Q, Pharmacol Ther 2005 106 2 147 162 10.1016/j.pharmthera.2004.11.006 15866317 (Pubitemid 40613056)